Gene therapy aims to address genetic disorders by introducing healthy genes into cells to replace or supplement defective ones.

Naked DNA injection is not a widely used method for gene delivery due to its low efficiency in introducing genes into cells.

Cystic fibrosis is one of the most common genetic disorders treated with gene therapy, aiming to introduce a functional copy of the CFTR gene to correct the underlying defect.

Viral vectors can trigger an immune response in the body, leading to side effects and potential rejection of the gene therapy.

Ex vivo gene therapy involves modifying cells outside the body, such as stem cells, before transplanting them back into the patient.

Germline gene therapy raises ethical concerns due to its potential to alter the genetic heritage of future generations.

CRISPR-Cas9 is a widely used gene editing tool that allows researchers to make precise changes to DNA sequences.

Gene editing in gene therapy aims to repair or replace defective genes with functional ones to correct genetic disorders.

Gene therapy is primarily used for treating genetic diseases, not for enhancing athletic performance.

Viral vectors are commonly used in gene therapy due to their high efficiency in delivering genes into cells.

In vivo gene therapy involves modifying genes directly within the patient's body, without removing cells from the body.

Somatic gene therapy carries the risk of side effects in the patient, as it involves modifying genes in somatic cells.

Gene therapy is primarily used for treating genetic diseases, not for enhancing physical appearance.

Gene editing in gene therapy carries the risk of unintended genetic changes, known as off-target effects.

In vivo gene therapy is not a type of gene therapy based on the target cells, as it refers to the method of gene delivery directly within the patient's body.